Truvada[®] for pre-exposure prophylaxis (PrEP) Registration In The Developing World

Approved

1. Brazil	May 2017	5.	Nigeria	December 2017	9.	Tanzania	December 2016
2. Chile	May 2017	6.	Peru	March 2016	10	Uganda	December 2017
3. Kenya	November 2015	7.	South Africa	November 2015	11	Zambia	April 2017
4. Malawi	February 2017	8.	Thailand	August 2016	12	Zimbabwe	March 2017

Filed

1.	Ecuador	July 2017

Terms and Definitions

Approved: Dossier submitted and approved by country or no formal regulatory process in place; approval confirmed by country.

Filed: Dossier submitted and review pending.

Note

There can be no guarantee that marketing approval for Truvada[®] for pre-exposure prophylaxis (PrEP) will be granted in any of the low- and middle-income countries where registration is pending; any marketing approval, if granted, may have significant limitations on its use.

